Hemab Therapeutics Holdings, Inc.
COAG
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders. Hemab Therapeutics Holdings, Inc. is advancing a pipeline of treatments designed to address serious inherited bleeding conditions, including Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its lead programs include sutacimig (HMB-001), a bispecific antibody, and HMB-002, a monovalent antibody, both being studied in clinical development for prophylactic use. The company’s work centers on bleeding and coagulation biology, with an emphasis on therapeutic approaches that target underlying disease mechanisms rather than symptom management. Hemab Therapeutics Holdings, Inc. operates as a research-driven biotechnology business serving the rare disease and hematology markets.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$0.00
Net Income (FY)
-$64M
▼ -31.2% YoY
Op. Margin
–
ROIC
-3761.90%
▼ -1454.5pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-$61M
▼ -34.0% YoY
Op. Cash Flow (FY)
-$61M
▼ -34.8% YoY
Net Debt
-$184M
Net Cash Position
Cash & Equiv.
$185M
Continue Research
Peers
Biotechnology · Pick stocks to compare with COAG
Held by ETFs
COAG is in 11 US ETFs. The largest of them, with COAG's weight in each:
Hemab Therapeutics Holdings (COAG) in two numbers
Questions about Hemab Therapeutics Holdings
Is Hemab Therapeutics Holdings a high-quality business?
Hemab Therapeutics Holdings scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from company filings. Its best check is net debt at -$184M, and its weakest is return on capital at -3761.9%. The Quality tab shows every check against its target.
Does Hemab Therapeutics Holdings (COAG) pay a dividend?
No. Hemab Therapeutics Holdings (COAG) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing COAG
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.